In Vitro Activity of Ceftolozane-Tazobactam against Enterobacter cloacae Complex Clinical Isolates with Different β-Lactam Resistance Phenotypes | Zendy

Frédéric Robin | Zendy; Michel Auzou | Zendy; Richard Bonnet | Zendy; Romain Lebreuilly | Zendy; Christophe Isnard | Zendy; Vincent Cattoir | Zendy; François Guérin | Zendy

Open Access

In Vitro Activity of Ceftolozane-Tazobactam against Enterobacter cloacae Complex Clinical Isolates with Different β-Lactam Resistance Phenotypes

Author(s) -

Frédéric Robin,

Michel Auzou,

Richard Bonnet,

Romain Lebreuilly,

Christophe Isnard,

Vincent Cattoir,

François Guérin

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00675-18

Subject(s) - enterobacter cloacae , microbiology and biotechnology , enterobacter , tazobactam , biology , in vitro , enterobacteriaceae , enterobacteriaceae infections , antibiotics , antibiotic resistance , gene , escherichia coli , imipenem , genetics

The study evaluated the in vitro activity of ceftolozane-tazobactam (C/T) against 94 unique clinical isolates of Enterobacter cloacae complex (ECC). No difference was observed according to the ECC cluster. The in vitro activity greatly varied depending on the β-lactamase-producing profile: 100%, 67%, and 19% of wild-type, extended-spectrum β-lactamase (ESBL)-producing, and AmpC-overproducing strains, respectively, were susceptible to C/T. The use of C/T could be of interest for the treatment of some infections caused by ESBL-producing AmpC-nonoverexpressing ECC isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research